CC
ICPT

Centiva Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Centiva Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,778
Closed -$317K – 955
2019
Q3 		$317K Buy
+4,778
New +$321K 0.02% 427

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Centiva Capital's ICPT Position: Q4 2019 in Review

Centiva Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2019, closing a stake of 4,778 shares — an estimated $317K sold.

Centiva Capital first reported a position in ICPT in Q3 2019 and held it in 1 quarter. The position peaked at $317K in Q3 2019. 215 funds tracked by Wall St. Rank hold ICPT as of Q4 2019.

  • Centiva Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Centiva Capital sold 4,778 Intercept Pharmaceuticals, Inc. shares in Q4 2019, an estimated $317K.
  • Centiva Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Centiva Capital's Intercept Pharmaceuticals, Inc. position peaked at $317K in Q3 2019.
  • 215 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2019.

Based on Centiva Capital's 13F filing for Q4 2019, filed 14 Feb 2020.